– Star’s innovation engine has driven rapid advancement of internally discovered first‑in‑class antibody therapeutics into the clinic, attracting leading life sciences investors– Financing supports Vega Therapeutics, a clinical stage company focused on underserved blood disorders, as well as the advancement of addit.
With $40 million in financing to date, company has advanced lead drug candidate, VGA039, to clinical stage to treat von Willebrand disease (VWD)Oral presentation at ASH will feature preclinical data of VGA039, a monoclonal antibody with potential to be a universal hemostatic therapy for bleeding disordersCompany has.